BioSpace News Archive

TORONTO, Feb. 14, 2023 /PRNewswire/ - MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication of “Point-of-care fluorescence imaging reveals extent of bacterial load in diabetic foot ulcers"1 in International Wound Journal.

Laborie Medical Technologies Corp., announced that it has acquired Novonate, Inc. and its LifeBubble technology, a device that revolutionizes umbilical catheter protection and securement to improve safety for neonates in the intensive care setting.

Asensus Surgical, Inc. announced a multi-year collaboration with Google Cloud to integrate Google Cloud’s secure cloud data architecture and machine learning technologies to further expand the capabilities of the Asensus Surgical’s Performance-Guided Surgery™ framework enabled through the Intelligent Surgical Unit ™.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, today announced the launch of Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs).

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Rectify Pharmaceuticals, Inc., (“Rectify”) today announced the appointments of Tuyen Ong, M.D., M.B.A., to the Board and Directors, and Jason Campagna, M.D., Ph.D., to the Scientific Advisory Board.

Research published in Nature Chemical Biology demonstrates a new tool for scientists studying conditions such as autism and Alzheimer’s disease.

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023.

Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California.